Barclays Increases LifeStance Health Group (NASDAQ:LFST) Price Target to $7.00

LifeStance Health Group (NASDAQ:LFST) had its price objective upped by Barclays from $6.00 to $7.00 in a report issued on Monday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

Separately, UBS Group lowered their price objective on shares of LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating on the stock in a research note on Thursday, August 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, LifeStance Health Group presently has a consensus rating of “Hold” and an average target price of $8.42.

LifeStance Health Group Trading Down 1.1 %

NASDAQ:LFST opened at $7.15 on Monday. LifeStance Health Group has a 52 week low of $4.64 and a 52 week high of $9.20. The company has a quick ratio of 1.22, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $6.98 and its two-hundred day moving average is $6.24.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.05. The firm had revenue of $312.70 million for the quarter, compared to analyst estimates of $302.25 million. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The firm’s revenue for the quarter was up 18.9% on a year-over-year basis. During the same period last year, the company earned ($0.17) earnings per share. On average, research analysts predict that LifeStance Health Group will post -0.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, insider Ann Varanakis sold 5,269 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $6.28, for a total transaction of $33,089.32. Following the sale, the insider now directly owns 263,007 shares of the company’s stock, valued at $1,651,683.96. The trade was a 1.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paloma Partners Management Co acquired a new position in LifeStance Health Group during the third quarter worth $176,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in LifeStance Health Group by 10.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 516,819 shares of the company’s stock worth $3,618,000 after buying an additional 48,634 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of LifeStance Health Group by 31.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,105 shares of the company’s stock worth $169,000 after buying an additional 5,767 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of LifeStance Health Group by 14.3% in the third quarter. MetLife Investment Management LLC now owns 80,422 shares of the company’s stock valued at $563,000 after acquiring an additional 10,084 shares during the period. Finally, Townsquare Capital LLC acquired a new stake in shares of LifeStance Health Group in the third quarter worth $73,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.